

OCT 17 2007

APPLICATION NO.: 10/616,865

ATTY. DOCKET NO.: A0906.70008US00

FILING DATE: July 9, 2003

CONFIRMATION NO.: ---

APPLICANT: Martha K. Newell

GROUP ART UNIT: 1644

EXAMINER: F. P. Vandervegt

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 3

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
*	2005/0074882	A1	Newell		04-07-2005
*	6,416,958	B2	Vidovic et al.		07-09-2002
*	4,971,951		Garcia y Bellon et al.		11-20-1990
*	5,286,653		Brenner et al.		02-15-1994

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
*	WO	97/16188			Merck & Co.	05-09-1997	
*	EP	0524796			Efamol Holdings PLC	01-27-1993	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
*	Berg, SL et al., J. N at. Cancer Inst. (1994) 86(2):143-145		
*	TAXOL product literature (Bristol-Myers Squibb (2003) pages 1-6		
*	Burrows et al., Cancer Research Inst. (1994) 86(2):143-145		
*	Ianniello, G.P., et al., Cancer (1996) 78(1):63-69		
*	Bristol Myers Squibb product information for TAXOL (pacitaxel), March 2003. Bristol Myers Squibb, Princeton, NJ, 6 pages		
*	BRYDER et al., Hematopoietic Stem Cells The Paradigmatic Tissue-Specific Stem Cell. Am J of Pathology, 2006 Aug; 169(2):338-346		
*	ROLL et al., Regeneration of B Cell Subsets After Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis, Arthritis & Rheumatism, 2006 Aug; 54(8):2377-2386		
*	WANG et al., Purified hematopoietic stem cells without facilitating cells can repopulate fully allogeneic recipients across entire major histocompatibility complex transplantation barrier in mice. Proc. Natl. Acad. Sci. 1997 Dec; Vol. 94: 14632-14636		
*	[No Author Listed] TAXOL Product Literature. Bristol Myers Squibb. 2003:1-6.		
*	BERG et al., Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst. 1994 Jan 19;86(2):143-5.		
*	BODMER et al., Identification of HLA-DP polymorphism with DP alpha and DP beta probes and monoclonal antibodies: correlation with primed lymphocyte typing. Proc Natl Acad Sci U S A. 1987 Jul;84(13):4596-600.		
*	CARREL et al., Recombinant interferon-gamma can induce the expression of HLA-DR and -DC on DR-negative melanoma cells and enhance the expression of HLA-ABC and tumor-associated antigens. Eur J Immunol. 1985 Feb;15(2):118-23.		
*	CRUMP et al., Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B-cell non-Hodgkin lymphoma: a Phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). Cancer. 2004 Oct 15;101(8):1835-42.		

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/616,865	ATTY. DOCKET NO.: A0906.70008US00		
				FILING DATE: July 9, 2003	CONFIRMATION NO.: ---		
				APPLICANT: Martha K. Newell			
				GROUP ART UNIT: 1644	EXAMINER: F. P. Vandervegt		
Sheet	2	of	3				

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*	DEEN et al., A soluble form of CD4 (T4) protein inhibits AIDS virus infection. <i>Nature</i> . 1988 Jan 7;331(6151):82-4.	
	*	FANCIULLI et al., Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells. <i>Oncol Res</i> . 1996;8(3):111-20.	
	*	HEDLEY et al., Assembly and peptide binding of major histocompatibility complex class II heterodimers in an in vitro translation system. <i>Proc Natl Acad Sci U S A</i> . 1994 Oct 25;91(22):10479-83.	
	*	HESS et al., A novel function of CD40: induction of cell death in transformed cells. <i>J Exp Med</i> . 1996 Jan 1;183(1):159-67.	
	*	HOON et al., Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. <i>Cancer Res</i> . 1991 Apr 15;51(8):2002-8.	
	*	IANNIELLO et al., Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial. <i>Cancer</i> . 1996 Jul 1;78(1):63-9.	
	*	KHOURY et al., Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. <i>J Immunol</i> . 1996 Oct 15;157(8):3700-5.	
	*	KUCHROO et al., B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. <i>Cell</i> . 1995 Mar 10;80(5):707-18.	
	*	LAMARRE et al., Class II MHC molecules and the HIV gp 120 envelope protein interact with functionally distinct regions of the CD4 molecule. <i>EMBO J</i> . 1989 Nov;8(11):3271-7.	
	*	MIZUNO et al., The proteolytic cleavage of protein kinase C isotypes, which generates kinase and regulatory fragments, correlates with Fas-mediated and 12-O-tetradecanoyl-phorbol-13-acetate-induced apoptosis. <i>Eur J Biochem</i> . 1997 Nov 15;250(1):7-18.	
	*	NEWELL et al., The effects of chemotherapeutics on cellular metabolism and consequent immune recognition. <i>J Immune Based Ther Vaccines</i> . 2004 Feb 2;2(1):3.	
	*	POSADA et al., Human multidrug resistant KB cells overexpress protein kinase C: involvement in drug resistance. <i>Cancer Commun</i> . 1989;1(5):285-92.	
	*	STASSI et al., Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. <i>J Exp Med</i> . 1997 Oct 20;186(8):1193-200.	
	*	SUZUKI et al., Activation of target-tissue immune-recognition molecules by double-stranded polynucleotides. <i>Proc Natl. Acad. Sci. U S A</i> . 1999 Mar 2;96(5):2285-90.	
	*	TANSAN et al., Augmentation of vincristine cytotoxicity by megestrol acetate. <i>Cancer Chemother Pharmacol</i> . 1997;39(4):333-40.	
	*	UTZ et al., The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. <i>Int J Cancer</i> . 1994 Apr 1;57(1):104-10.	
	*	WANG et al., Effects of cisplatin and taxol on inducible nitric oxide synthase, gastrin and somatostatin in gastrointestinal toxicity. <i>Anticancer Drugs</i> . 1997 Oct;8(9):853-8.	
	*	Burrows et al., <i>Cancer Research</i> 52:2954 Abstract	
		BURROWS, F. J. et al., A Murine Model for Antibody-directed Targeting of Vascular Endothelia Cells in Solid Tumors, <i>Cancer Research</i> , 52, 5954-5962, 1992	
		BLANCHETEAU, V. et al., HLA Class II Signals Sensitize B Lymphocytes to Apoptosis via Fas/CD95 by Increasing FADD Recruitment to Activated Fas and Activation of Caspases, <i>Human Immunology</i> 63, 375-383, 2002	
		NAGY, Z. et al., A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules, <i>J. Mol. Med</i> , 81:757-765, 2003	

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.:	10/616,865	ATTY. DOCKET NO.:	A0906.70008US00
				FILING DATE:	July 9, 2003	CONFIRMATION NO.:	---
				APPLICANT:	Martha K. Newell		
Sheet	3	of	3	GROUP ART UNIT:	1644	EXAMINER:	F. P. Vandervegt

EXAMINER: DATE CONSIDERED:

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/277,575, filed March 27, 1999, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]